# An abbreviated approval path for follow-on antibodies within a validated class

Source: https://onco.cc/ideas/idea-fund-abbreviated-pathway-me-too-biologics/  
OnCo record `idea-fund-abbreviated-pathway-me-too-biologics` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Once a class of antibody such as PD-1 blockers is proven, later copies could be approved on smaller trials showing equivalence, forcing price competition and freeing patients and money for genuinely new drugs.

## Summary

For mechanistic classes with multiple approved agents and well-understood pharmacology (anti-PD-1, anti-CD20, anti-HER2), regulators create a pathway between biosimilar approval and a full new-drug approval: approval based on pharmacodynamic equivalence and a single non-inferiority efficacy trial against an approved class member, with pricing expected to follow biosimilar dynamics. This ends the wasteful situation in which each of a dozen PD-1 antibodies runs its own placebo- or chemotherapy-controlled phase 3 in populations already known to benefit, while giving payers real competition within class. Capital that cannot earn novel-drug returns on copies moves elsewhere.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: An abbreviated class pathway reduces net prices of the affected class by at least 30% within three years of the first abbreviated approval and reduces the number of full-scale placebo-controlled phase 3 trials of later-in-class agents in the class.
- Rationale: Biosimilar pathways cut prices for rituximab and trastuzumab substantially in Europe; several later PD-1 antibodies approved in China are already priced far below Western incumbents. The clinical pharmacology of these classes is well enough understood that repeating full development adds little knowledge.
- Proposed test: Regulator consultation and a pilot pathway for one class (anti-PD-1) with defined equivalence criteria, tracking approvals, trial designs and net prices over four years.
- Maturity: speculative
- Actor: regulator

## Sources

- Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022): https://doi.org/10.1038/d41573-022-00030-4

## Connected records

- ideas: [Require head-to-head trials against the best in class for later entrants](https://onco.cc/ideas/idea-fund-head-to-head-mandate/), [Shorter exclusivity for later-in-class drugs without added benefit](https://onco.cc/ideas/idea-fund-benefit-indexed-exclusivity/)
- targets: [CD20](https://onco.cc/targets/cd20/), [HER2](https://onco.cc/targets/her2/), [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- bottlenecks: [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/), [Trial design, endpoints and cost](https://onco.cc/bottlenecks/b-trial-design/)
- key papers: [Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape](https://onco.cc/key-papers/paper-upadhaya-nat-rev-drug-discov/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-abbreviated-pathway-me-too-biologics.json